Physician profile
Farris Blount
NPI 1275550162
$4,923.61
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2020: $867 · 2021: $1,434 · 2022: $1,354 · 2023: $541 · 2024: $18.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $558.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $953.54 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $880.07 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $713.30 | 2019-2023 | Mounjaro, Emgality, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $398.01 | 2021-2023 | |
| Glaxosmithkline, LLC. | $224.38 | 2020-2023 | Trelegy Ellipta |
| Roche Molecular Systems, INC. | $200.00 | 2022 | |
| Amarin Pharma, INC. | $187.21 | 2019-2022 | |
| Pfizer INC. | $178.65 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $141.45 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $136.33 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $126.96 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.97 | 2019-2023 | Jardiance |
| Arbor Pharmaceuticals, INC. | $109.09 | 2019-2021 | |
| Boston Scientific Corporation | $66.22 | 2019-2020 | |
| Abbvie INC. | $66.12 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $63.76 | 2021-2022 | |
| Genzyme Corporation | $60.00 | 2020 | |
| Gilead Sciences, INC. | $47.89 | 2021-2022 | |
| Sanofi Pasteur INC. | $42.27 | 2019-2020 | |
| Esperion Therapeutics, INC. | $37.82 | 2021 | |
| Exact Sciences Corporation | $22.80 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $18.32 | 2020 | |
| Aimmune Therapeutics, INC. | $18.15 | 2024 | |
| Eisai INC. | $17.93 | 2021 | |
| Optinose US, INC. | $17.87 | 2020 | |
| Genentech USA, INC. | $17.82 | 2019 | |
| Valeritas, INC. | $17.35 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.53 | 2021 | |
| Shield Therapeutics INC | $13.02 | 2023 | Accrufer |
| Allergan, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farris Blount listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.